๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials

โœ Scribed by Qian Shi; Daniel J. Sargent

Publisher
Springer
Year
2009
Tongue
English
Weight
254 KB
Volume
14
Category
Article
ISSN
1341-9625

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Screening for ovarian cancer: What are t
Screening for ovarian cancer: What are the optimal surrogate endpoints for clinical trials?
โœ Beth Y. Karlan ๐Ÿ“‚ Article ๐Ÿ“… 1995 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 634 KB

The inability to identify relevant markers for presymptomatic screening in early stage or "preinvasive" ovarian cancer has plagued investigators and clinicians facing the problems of early detection. The characteristic late stage of disease at initial presentation has hindered our understanding of t

Meta-analysis for the evaluation of pote
Meta-analysis for the evaluation of potential surrogate markers
โœ Michael J. Daniels; Michael D. Hughes ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 171 KB ๐Ÿ‘ 2 views

We describe a meta-analysis approach for the evaluation of a potential surrogate marker. Surrogate markers are useful in helping to identify therapeutic mechanisms of action and disease pathogenesis, and for selecting therapies to take forward from phase II to phase III clinical trials. They have al

Resampling-based methods for the analysi
Resampling-based methods for the analysis of multiple endpoints in clinical trials
โœ Peter Reitmeir; Gernot Wassmer ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 95 KB ๐Ÿ‘ 2 views

We consider multivariate tests for comparing two treatments with multiple endpoints. The test decision is drawn from the simultaneous consideration of the univariate tests for the single endpoints. A general class of these tests, called cut-o! tests, can be given, which, however, can lead to highly